HLB Co., Ltd. HLB Co., Ltd.

HLB Co., Ltd.

028300

株式のランク #4148
HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and... HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and naval construction. In South Korea, its maritime division produces and distributes a diverse range of lifeboats, catering to offshore platforms, drilling vessels, and passenger cruise liners. Its offerings include traditional, free-fall, and rescue boat designs. Beyond lifeboats, HLB's product portfolio extends to marine and yacht engines, hooks, and a variety of specialized vessels such as rigid inflatable (RIB), patrol, fishing, aluminum, and leisure boats, as well as fishery inspection ships and general safety equipment. The company further offers comprehensive support services, including inspection and repair of lifeboats and davits, service engineering training, and the provision of spare parts. On the pharmaceutical front, HLB is engaged in the development of Riboseranib, a targeted anti-cancer agent, and Apilia, a treatment specifically for ovarian cancer. Established in 1975, HLB Co., Ltd. is headquartered in Ulsan, South Korea.
株価
$29.28
時価総額
$3.89B
変化(1日)
-1.40%
変化(1年)
-8.45%
国
KR
取引 HLB Co., Ltd. (028300)

カテゴリー

Healthcare
HLB Co., Ltd.(028300)の利益
Jun 2026 時点の利益 TTM: $-160.32M
HLB Co., Ltd. の最新の財務報告によると、同社の現在の利益は $-160.32M です。2023 年には $-164.38M の利益を上げ、これは 2022 年の利益 $-62.61M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
HLB Co., Ltd. の利益の推移(2012 〜 2026)
各年末の利益
年 利益 変化
2026 (TTM) $-160.32M 115.74%
2024 $-74.31M -54.79%
2023 $-164.38M 162.55%
2022 $-62.61M -27.09%
2021 $-85.87M 12.36%
2020 $-76.43M 43.17%
2019 $-53.38M -540.23%
2018 $12.13M -138.75%
2017 $-31.29M 69.49%
2016 $-18.46M -310.93%
2015 $8.75M -632.68%
2014 $-1.64M -80.80%
2013 $-8.56M 40.17%
2012 $-6.11M 0.00%
同業他社の利益
企業 利益 利益の差 国
$5.27B -3,390.24%
US
$-3.09B 1,825.53%
US
$-4.02B 2,405.12%
AU
- -
CH
$1.95B -1,316.72%
NL